Aclaris Therapeutics (ACRS) Stock Statistics & Valuation Metrics

Aclaris Therapeutics has a market cap or net worth of $167.84M. The enterprise value is $137.48M.

Aclaris Therapeutics has 108,281,240 shares outstanding. The number of shares has decreased by -2.65% in one year.

Aclaris Therapeutics’s return on equity (ROE) is -0.85 and return on invested capital (ROIC) is -75.20%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, Aclaris Therapeutics had revenue of 18.72M and earned -132.06M in profits. Earnings per share was -1.71.

In the last 12 months, operating cash flow was -18.99M and capital expenditures -644.00K, giving a free cash flow of -19.64M billion.

Aclaris Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Aclaris Therapeutics upcoming earnings date is Aug 6, 2025, Before Open (Confirmed).

Aclaris Therapeutics as a current ratio of 3.99, with Debt / Equity ratio of 0.00%

In the past 12 months, Aclaris Therapeutics has paid 0.00 in taxes.

Aclaris Therapeutics EV to EBITDA ratio is -3.23, with an EV/FCF ratio of -8.28.

Aclaris Therapeutics has $105.31M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$105.31M billion.

Gross margin is 20.55%, with operating margin of -758.18%, and net profit margin of -705.48%.

The average price target for Aclaris Therapeutics is $9.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy